Vol. 3 No. 2 (2023)
Reimbursement Reviews

Pembrolizumab (Keytruda)

Published February 6, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pembrolizumab (Keytruda), solution for infusion, 100 mg/4 mL vial.
  • Indication: Indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.